Medical Cannabis & RegulationGerman Court Limits Online Cannabis Treatment Advertising
March 26, 2026
A recent ruling by Germany’s Federal Court of Justice (BGH) restricts how companies can advertise medical cannabis treatments online. The decision impacts platforms like Bloomwell, which connect patients with doctors, and signals a tightening of regulations around direct-to-consumer marketing of prescription drugs.
The BGH ruled that advertising for medical cannabis treatments via online portals is prohibited under German law, as it violates regulations concerning the advertising of prescription medications. The court emphasized that it doesn’t matter if specific products or manufacturers are named.
The Bloomwell Case and the Core of the Dispute
The case centered on Bloomwell, a Frankfurt-based company that facilitates connections between patients and physicians for medical cannabis prescriptions. Bloomwell receives compensation from doctors for these referrals. The company argued its services provide information about a treatment option, not direct advertising of a product. However, the Federal Competition Centre challenged this, arguing it violated Germany’s medicinal products advertising law.
The court sided with the Federal Competition Centre, confirming that internet platforms are not permitted to advertise medical cannabis treatments directly to patients. Advertising of prescription drugs is restricted to healthcare professionals – doctors, pharmacists, and pharmaceutical retailers.
Impact on Consumer Information Access
Bloomwell’s CEO, Niklas Kouparanis, stated the ruling restricts consumer access to information about medical cannabis. He believes the legal situation is now clarified for the company and its competitors, and doesn’t anticipate the need for new legislation. However, the decision raises questions about how patients will discover and learn about medical cannabis treatment options.
Government Plans for Stricter Regulation
The ruling comes as the German government considers stricter regulations for medical cannabis. Health Minister Nina Warken aims to curb potential misuse of the drug.
Medical cannabis has been legally prescribed in Germany since 2017 and is used to treat conditions such as chronic pain, muscle spasms associated with multiple sclerosis, nausea and vomiting resulting from chemotherapy, and unintended weight loss.
What This Means for Telemedicine Platforms
The BGH’s decision has significant implications for telemedicine platforms offering medical cannabis prescriptions. These platforms will need to carefully review their marketing strategies to ensure compliance with the new ruling. The focus will likely shift towards providing information to healthcare professionals rather than directly targeting patients.
Frequently Asked Questions
What does this ruling imply for patients seeking medical cannabis?
Patients will likely have fewer online resources for finding information about medical cannabis treatments and connecting with doctors.
Does this ruling affect the legality of medical cannabis prescriptions?
No, the ruling does not change the legality of medical cannabis prescriptions in Germany. It only affects how these treatments can be advertised.
What is Bloomwell’s response to the ruling?
Bloomwell’s CEO believes the legal situation is now clarified and doesn’t anticipate needing new laws, but acknowledges the ruling restricts consumer information access.
